https://citarinostatinhibitor.....com/setup-and-also-e
Patient data from the ongoing phase I clinical trial (NCT04820023) are also available. BBT-176's half-maximal inhibitory concentration (IC5 against EGFR 19Del/C797S, EGFR 19Del/T790M/C797S, and EGFR L858R/C797S was measured at 436, 179, and 535 nmol/L, respectively. Osimertinib was measured at 30439, 12482, and 57372 nmol/L in the study. Regarding Ba/F3 cells with EGFR mutations,
Like
Comment
Share
